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ABSTRACT
Breast Cancer Risk Assessment:
Evaluation of Screening Tools for Genetics Referral
Maren Lothyan Zaro
College of Nursing, BYU
Master of Science
Purpose: This study assessed effectiveness of five tools recommended by the US
Preventive Services Task Force (USPSTF), designed to help primary care clinicians
determine which unaffected patients to refer to genetics specialists for breast cancer risk
assessment based on concerning family history.
Design: This descriptive secondary analysis included 85 women aged 40-74. All
participants had a first-degree female relative previously diagnosed with breast cancer who
also had uninformative negative BRCA1/2 tests.
Methods: Each pedigree was evaluated using the five tools including the Family
History Screen-7 (FHS-7), Pedigree Assessment Tool (PAT), Manchester Scoring System,
Referral Screening Tool (RST), and Ontario-Family History Assessment Tool (OntarioFHAT). All five tools were applied to each study participant. Sensitivity, specificity, positive
predictive value, and negative predictive value were calculated to describe each tool’s ability
to identify women with elevated risk as calculated by the Claus model. Receiver operating
curves (ROC) were also plotted. Differences between areas under the curve (AUCs) for all
possible pairs of tools were estimated through logistic regression to assess for differences in
tool performance.
Results: Claus calculations identified 14 women out of 85 whose lifetime risk of
breast cancer was elevated at > 15%. Only two tools, the Ontario-FHAT and FHS-7,
identified all 14 women with elevated risk, a sensitivity of 100%. The FHS-7 tool flagged all
85 participants, meaning its specificity was zero. The Ontario-FHAT flagged 59 participants
as needing referral (specificity 36.2%) and had a negative predictive value (NPV) of 100%,
indicating that if a woman was not found to need a referral to a genetics professional, it is
likely she did not have an elevated lifetime risk of developing breast cancer. AUC values
were not significantly different between tools (all p values > .05), and thus were not helpful
in discriminating between the tools.
Conclusion: In this population, the Ontario-FHAT out-performed other tools in terms
of sensitivity and negative predictive value; however, low specificity and positive predictive
value must be balanced against these findings. Thus, the Ontario-FHAT can help determine
which women would benefit from referral to a genetics specialist.
Keywords: risk assessment, medical management, breast cancer screening, BRCA1/2,
USPSTF, hereditary breast cancer, FHAT, FHS-7, PAT, Manchester, RST
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Breast Cancer Risk Assessment:
Evaluation of Screening Tools for Genetics Referral
Introduction
Recently, the United States Preventative Services Task Force (USPSTF) recommended
that asymptomatic women who have not been diagnosed with breast cancer but who have
concerning family history, including family members with breast, ovarian, tubal or peritoneal
cancers, be assessed for cancer risk (Moyer, 2014). Although some clinicians may be skilled at
performing in-depth risk assessments, others may opt to refer patients to genetics specialists for
assessment. Therefore, to help clinicians identify patients who need referral, the USPSTF
recommended primary care providers (PCPs) screen women by applying one of five screening
tools (Moyer, 2014). The screening tools are designed to identify women who may have greater
likelihood of developing breast cancer (Moyer, 2014). The USPSTF did not identify which tool
is best for identifying patients needing referral (Moyer, 2014).
Background
The burden of disease caused by breast cancer is significant. Breast cancer is second only
to skin cancer as the most common cancer in women (National Institute of Health (NIH), 2014).
In 2016 in the United States (US), it is estimated more than 246,660 women will be newly
diagnosed with breast cancer (NIH, 2016). The cost of breast cancer care for 2014 was estimated
(in 2010 dollars) at 17.2 billion dollars in the US alone (NIH, 2014).
Guidelines for breast cancer screening vary based on individual risk. Because age of
initiation, type, and frequency of screening varies, identifying women at elevated risk for breast
cancer is essential to recommending appropriate screening. Women at increased risk of breast
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cancer may be offered earlier screenings, beginning at age 30 (or earlier, depending on family
history), and/or screening that includes annual MRI in addition to annual mammograms
(National Comprehensive Cancer Network, 2014; Saslow et al., 2007). Therefore, if individual
risk is not calculated, women may not receive appropriate type and frequency of screening.
Multiple risk assessment models are available to calculate lifetime breast cancer risk. Models
may estimate breast cancer risk differently because they include different risk factors or weigh
risk factors differently (Ozanne et al., 2013; NIH, 2016). Some risk models use only pedigree
analysis, while other models include additional breast cancer risk factors such as early menarche
or delayed childbearing. Only risk models that include extensive family history should be used
for recommending annual screening breast MRI (National Comprehensive Cancer Network,
2015; Saslow et al., 2007; NIH, 2016). See Table 1 for risk assessment models that use extensive
family history. For this reason, the Gail model (also known as the Breast Cancer Risk
Assessment Tool) should not be used for determining need for screening MRI because it utilizes
limited family history. (Saslow et al., 2007; NIH, 2016).
Use of risk assessment models can be complex. During an office visit, a PCP may not
have the time to calculate breast cancer lifetime risk. Additionally, models available require
specialized software and clinical time to enter data. Because PCPs may lack the time or expertise
to calculate breast cancer lifetime risk (Hampel, Bennett, Buchanan, Pearlman & Wiesner,
2015), the USPSTF has recommended five screening tools (Moyer, 2014) to identify patients
who would benefit from referral to genetics professionals for in-depth risk assessment (Table 1).
The USPSTF did not identify which tool is superior. Therefore, the purpose of this study was to
assess the effectiveness of five tools recommended by the USPSTF in identifying women at
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elevated breast cancer risk. Use of these tools will then allow for appropriate genetic professional
referral for risk assessment and, if appropriate, genetic mutation testing.
Methods
This descriptive study, using secondary analysis of data from previous research (Himes,
Clayton, Donaldson, Ellington, Buys & Kinney, 2015), evaluated the sensitivity, specificity,
positive and negative predictive values, and receiver operating curves (ROC) for five screening
tools. Data related to family history and risks for breast cancer were collected from 85 women
through written surveys and telephone interviews. Institutional review board (IRB) approval was
obtained for the original research and all participants gave informed consent (Himes et al., 2015).
IRB approval was obtained separately for this study.
Participants
Participants included 85 women between the ages of 40 and 74. All participants were
sisters or daughters of women who had a personal history of breast cancer and who had received
uninformative negative genetic testing for BRCA1/2 gene mutations results from a board
certified genetic counselor (Himes et al., 2015). Women were excluded if they had ever received
breast cancer-related genetic testing, had received a prophylactic bilateral mastectomy or
oophorectomy, had a personal history of any type of cancer other than non-melanoma skin
cancer, and/or if they were of Ashkenazi Jewish descent, as the associated high-risk status with
this ancestry necessitates special consideration in evaluating risk.
Measurement
Risk for breast cancer was assessed using the Claus model and five screening tools. The
Claus model was used as the standard against which the five screening tools were evaluated.
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Screening tools were considered effective if they could identify women with Claus lifetime risk
>15% as needing referral to a genetics professional.
Claus model. Lifetime risk for breast cancer was calculated for 85-study participants
using the Claus model (Claus, Risch & Thompson, 1994) as part of the parent study (Himes et
al., 2015). The Claus model is known to be moderate in its risk projections when compared to
other risk assessment models (Ozanne et al., 2013). Additionally, both the NCCN (2015) and the
ACS (Saslow et al., 2007) recommend the Claus model as appropriate for calculation of breast
cancer lifetime risk for the purpose of ordering breast MRI.
The Claus model uses family history of first- and second-degree relatives with breast and
ovarian cancer to estimate lifetime risk (up to age 79) of breast cancer (Amir, Freedman, Seruga
& Evans, 2010). The model includes information regarding age at disease onset and cancer
history from both paternal and maternal family lines (Claus, Risch & Thompson, 1994).
For the purpose of this study, women with a Claus breast cancer lifetime risk estimate of
>15% were considered to be at elevated risk—in other words, we counted screening tools as
appropriately referring women if their lifetime risk calculation was >15%. Although 20%
lifetime risk is the cut point at which several breast cancer-screening guidelines begin to
recommend MRI, we selected 15% as a cut point for three reasons. First, over-referral is
preferable to under-referral in a screening test (Warner, 2004). If 20% were the threshold, fewer
women would be identified as needing referral; however, some would be missed who could
benefit from risk assessment. Second, women with risks calculated in the 15–20% range may
not actually be over-referred. In fact, American Cancer Society notes there is not sufficient
evidence to recommend for or against screening breast MRI in women with lifetime risks

BREAST CANCER RISK ASSESSMENT

5

between 15–20% (American Cancer Society, 2015). Finally, the Claus model provides lower risk
calculations than some other commonly used risk assessment models (Ozanne, 2013). Therefore,
setting >15% lifetime breast cancer risk as a cut point for referral recognizes that women not at
elevated risk by the Claus model could be found to be at elevated risk by other models. Thus, a
15% cut point provides a reasonable buffer allowing for variance between risk assessment
models (Ozanne, 2013; NIH, 2016).
Screening Tools to Guide Referral. The five tools in this study were recommended by
the USPSTF as primary screening tools for patients who may be at increased risk for breast
cancer due to family history (Moyer, 2014). The recommended tools include the Family History
Assessment Tool (FHAT), also known as Ontario-Family History Assessment Tool (Gilpin,
Carson & Hunter, 2000). In this paper we will refer to this tool as Ontario-FHAT. The other four
tools include the Manchester Scoring System (Evans et al, 2004); the Referral Screening Tool
(RST) (Bellcross, Lemke, Pape, Tess & Meisner, 2009); the Family History Screen-7 (FHS-7)
(Ashton-Prolla et al., 2009); and the Pedigree Assessment Tool (PAT) (Hoskins, Zwaagstra &
Ranz, 2006).
All tools rely on patient knowledge of family history. Accurate recall and knowledge of
cancer history to second or third degree relatives is key. Each tool can be completed with paper
and pencil, and each takes 5 minutes or less to perform and score. An understanding of how to
read pedigrees is essential. Clinicians should refer to specific instructions regarding how to score
and the cut points for referral related to each tool as found in the original articles cited in Table 2.
Initially each tool was developed and validated in populations of differing risk (Table 2).
Validation used in-depth risk assessment models and other methods of assessing breast cancer
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risk and/or likelihood of BRCA1/2 mutations rather than assessing their ability to predict breast
cancer, which may occur many years into the future. See Table 2 for tool description, initial
validation studies, validating population, and the gold standard measure against which it was
assessed.
Procedures. For this secondary analysis, 85 de-identified participant pedigrees and Claus
calculations from the parent study were accessed. Each pedigree was evaluated using all five
screening tools recommended by the USPSTF. Scores derived from each instrument were
compared to the participant’s lifetime risk as previously calculated by the Claus model to
determine each tool’s ability to identify women with >15% breast cancer lifetime risk. Women
with > 15% risk as identified in the parent study formed the “elevated risk” group in this
secondary analysis.
Data Analysis. Demographic data were described using means, standard deviations, and
percents as obtained through SPSS software version 22. Sensitivity and specificity for each
instrument were calculated to identify participants with Claus lifetime risk equal to or above
15%. Sensitivity reflects the proportion of individuals with an elevated lifetime risk of
developing breast cancer as identified by the Claus model who were correctly identified by the
screening tool as needing a referral. Specificity reflects the proportion of individuals who did not
have an elevated lifetime risk of developing breast cancer by the Claus model who were
correctly identified by the tool as not needing referral.
Positive and negative predictive values were also calculated for each tool. A positive
predictive value (PPV) represents the likelihood of having an elevated lifetime risk for breast
cancer as identified by the Claus model when the screening tool also suggests additional referral
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is indicated. A negative predictive value (NPV) indicates the likelihood of not having an elevated
lifetime risk for breast cancer as estimated by the Claus model when the screening tool suggests
referral is not needed.
For each screening tool, a receiver operating characteristic (ROC) curve was generated
with sensitivity along the y-axis and (1 minus specificity) along the x-axis. The area under the
ROC curve (AUC or C-statistic) is an indicator of the accuracy of a screening test. AUC values
close to 1.0 represent high levels of both specificity and sensitivity, while values near 0.5 or
below indicate lack of adequate specificity and sensitivity because no more cases would be
identified as needing referral than by chance alone. An AUC of 0.7 to 0.8 represents good
discriminatory accuracy (Amir, Freedman, Seruga & Evans, 2010). The ROC curves and the
statistics used for testing differences between ROC curves were estimated through logistic
regression using SAS software version 9.4.
Results
Participants were primarily Caucasian and married; all were older than age 40 (Table 3).
The Claus calculations identified 14 of 85 (16%) women whose lifetime risk for breast cancer
was > 15%. Sensitivity, specificity, PPV, NPV, and AUC for each instrument are presented in
Table 4. Sensitivity of the tools ranged from 57.1 to 100, and specificity from 0 to 64.8. Only the
Ontario-FHAT and FHS-7 identified all 14 women with elevated risk as needing referral (Table
4). However, the FHS-7 tool flagged all 85 participants as needing referral to a genetic specialist
for further analysis and risk assessment.
AUC values for the tools ranged from 0.65 to 0.72 (Figure 1). Chi-square analyses from
the logistic regressions were run between each possible pair of tools. All p values were > 0.05,
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indicating that no tool performed significantly differently from another. Thus, AUC values were
not helpful in discriminating between these tools.
The performance of the Ontario-FHAT was further evaluated by difference in age among
women who were referred and found to be at elevated risk by the Claus model (true positives) vs.
those who were referred and found to not have elevated risk (false positives or over-referrals).
Women who were over-referred had a significantly higher average age (55 years old on average)
than those who were appropriately referred (47 years old on average), p=0.0098. This indicates
that if the Ontario-FHAT identifies an older woman as needing referral, she is ultimately less
likely to be found to have elevated lifetime risk when a full risk assessment calculation is
performed (via risk assessment model) when compared to a younger woman.
Discussion
Calculating lifetime breast cancer risk is a complex process, but critical for
recommending appropriate screening in cases where family history is suspect. To help with
decisions regarding which patients to refer, the USPSTF issued guidelines in 2014 intended to
simplify the task (Moyer, 2014). However, the USPSTF did not give recommendations regarding
which tool was superior, stating the evidence was insufficient to make a recommendation
(Moyer, 2014). This study may be the first attempt to compare all five recommended screening
tools to each other.
This study compared the performance of five USPSTF recommended screening tools to
Claus model calculations of lifetime breast cancer risk for unaffected women, all of whom had a
sister or mother affected by breast cancer. In assessing how each tool performed, of particular
interest are 14 of the 85 women whose lifetime risk of developing breast cancer was calculated at
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> 15% per the Claus model. In evaluating tool performance, it was important that the tool had the
ability of to identify all 14 women in the elevated risk category. Only two of the five tools met
this standard; the Ontario-FHAT and the FHS-7, thus both had sensitivities of 100%.
Although the FHS-7 had a sensitivity of 100%, it recommended all 85 women be
referred, giving it a specificity of 0%, making it of little clinical utility. Since this tool refers any
woman with a single first-degree relative with breast cancer, regardless of the relative’s age at
diagnosis, every woman in our study would have been referred to genetics professionals. A
100% referral rate is inefficient, and could overload the health care system. Harms of an
overloaded health care system may include increased costs and wait times for services. Longer
wait times may cause increased anxiety for patients.
In contrast, Ontario-FHAT proved more useful in this sample, identifying all 14 women
in the elevated risk group as needing referral, giving it a sensitivity of 100%. Its NPV was 100%,
meaning if it did not identify a patient as needing referral to a genetics professional, it is likely
that person did not have an elevated lifetime risk of developing breast cancer (identified as >
15% lifetime breast cancer risk by the Claus model).
The Ontario-FHAT did not outperform the other tools in all parameters. It had a
comparatively low specificity (36.62%). This is not unexpected, as sensitivity and specificity
have an inverse relationship in a screening tool (Warner, 2004). The tradeoff between sensitivity
and specificity is that to attain high sensitivity (identifying all members of the elevated risk
group), the tool can be expected to over-refer, decreasing specificity. Conversely, if sensitivity is
decreased, meaning some members from the elevated risk group are not identified, specificity
can be expected to increase because over-referrals will decrease (Warner, 2004). Thus, because
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the goal of a screening tool is to identify all women at elevated risk, a higher sensitivity with the
resulting lower specificity is desirable. Additionally, if a tool missed women at elevated risk, we
not only miss an opportunity to screen not only the individual, but her family members as well,
who may also be at additional risk.
The Ontario-FHAT had a low PPV at 23.73, although not the lowest. The PPV reflects
the likelihood of a woman having elevated risk if the tool identified her as needing referral
(Warner, 2004). For a screening tool, it is reasonable to refer some women at lower risk in
preference to missing any women at elevated risk (Warner, 2004), so the low PPV is not
undesirable. Additionally, for conditions with low prevalence (in this study, the prevalence of
women with elevated risk was 16%), lower PPVs are expected (Warner, 2004). Therefore, a low
PPV is not necessarily a negative finding for the Ontario-FHAT.
Overall, the Ontario-FHAT outperformed the other tools. The combination of 100%
sensitivity and 100% NPV should reassure clinicians that when the Ontario-FHAT excludes an
individual from referral the individual is unlikely to be at elevated risk.
Limitations
Study limitations include a racially homogenous sample, which may limit application to
more diverse populations. In addition, written pedigrees previously collected were used to
complete the screening tools rather than using face-to-face interviews. Therefore, at times
assumptions about the family history were necessary which may have altered the data. For
example, since we did not have the exact age of menopause for each relative affected with
cancer, we counted cancers as occurring prior to menopause if they occurred at age 50 or
younger because the average age of menopause is 51 in the United States (National Institutes of
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Health, 2015). These assumptions affected the scoring of the tools and could have varied had we
conducted interviews in person.
Additionally, this study is limited by the age of participants. Future researchers should
consider including participants as young as age 30 because screening guidelines (Saslow et al.,
2007) for high-risk populations differ beginning at that age, and because lifetime risk is higher
for younger individuals as they have more lifetime ahead.
Clinical Implications
As medicine moves into what has been termed the genomic era, clinicians must be
prepared to care for the unique and changing attributes of individual patients. It is more effective
to provide screening tests such as breast MRI for individuals at higher risk for disease than to
screen entire populations. Assessing breast cancer risk in primary care settings is an ongoing
process. Clinicians must be aware that a one-time family history assessment is not sufficient.
Family history is dynamic (American College of Obstetricians and Gynecologists, 2015). As
additional family members receive cancer diagnoses, an individual’s risk estimate may rise.
Similarly, an individual’s risk level may decrease over time - as age increases, lifetime risk for
cancer decreases because there is less time to develop illness.
In addition to changing individual risk, clinicians must also be aware of changes in breast
cancer screening guidelines and risk assessment models. Recent research suggests it may be
better to use 10-year risk estimates rather than lifetime risk scores to determine when breast MRI
should be offered as part of an annual screening (Quante, Whittemore, Shriver, Hopper, Strauch
& Terry, 2015).
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Although the USPSTF screening tools are simpler to use than risk assessment models that
calculate lifetime risk (Table 1), clinicians need to be aware of limitations of the tools. None of
the screening tools account for age in assigning risk. Therefore, the tools may overestimate the
need for referral in older women. Additionally, scoring the tools can be complex. Each tool is
scored differently, and each varies in information considered. Clinicians should carefully
supervise office staff if collection of data and scoring these tools is delegated, especially as staff
learns to use and score the tools.
Clinicians may question if it is not more effective to order genetic tests for all patients
with concerning family histories and/or those who are concerned about breast cancer risk.
Certainly, the cost of genetic testing has dropped and inexpensive multi-gene panels are now
available. However, patients and clinicians must understand that lack of a positive result does
not rule out a hereditary basis for the cancer. Similarly, lack of a positive result does not mean
risk is low. Only 5 to 10% of breast cancers are thought to be hereditary (caused by heritable
genetic mutations) (NIH, 2016), and of those, only 10% are caused by BRCA1/2 mutations,
despite the fact that mutations in these genes are the most commonly identified cause of
hereditary breast cancer (NIH, 2016). Indeed, in this study population all 85 women had a
relative with an uninformative negative BRCA1/2 test, yet 16% were still at elevated risk for
developing breast cancer based on family history alone. Thus, while genetic testing can be
helpful, it is only part of the equation in caring for women with concerning family histories of
breast cancer.
Caring for women at risk for breast cancer is a collaborative process, yet deciding which
women to refer may be difficult for clinicians who are not specialists in cancer genetics (Hampel,
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Bennett, Buchanan, Pearlman, & Wiesner, 2015). PCPs may choose to refer patients based on
results of a brief screening tool such as those evaluated in this study, or after performing lifetime
risk calculation using a risk assessment model described in Table 1. There are advantages and
disadvantages to both options. PCP referral of individuals at elevated risk to genetics specialists
is recommended by several organizations, including NCCN (2015), Saslow et al. (2007) and
USPSTF (Moyer, 2014). Indeed, the USPSTF rates referring women suspected as being at
elevated risk for breast cancer to genetic specialists as a “grade B” recommendation, meaning
that it is a preventive service that should be covered by insurance with no cost or copay (Moyer,
2014).
An advantage of using the screening tools evaluated in this study is that they take
relatively little time to use. In primary care, this may be a significant advantage, as limited time
has been identified as a barrier to triggering genetic referrals (Hampel, Bennett, Buchanan,
Pearlman & Wiesner, 2015). A disadvantage to using these screening tools is that, as
demonstrated in this study, they may over- or under-refer. Additionally, some of these tools were
primarily designed to assess for the likelihood of carrying BRCA1/2 mutations. They do not
screen for other rare cancer syndromes, also potential causes of breast cancer. Finally, none of
the USPSTF recommended screening tools to guide referral are intended for the purpose of
ordering breast MRI; therefore, none of them has clinical utility beyond referral.
Similarly, there are advantages and disadvantages for PCPs learning how to use risk
assessment models. An advantage is that PCPs can order annual screening breast MRI based on
lifetime risk calculations using one of the appropriate models (Table 1). However, PCPs who run
their own lifetime risk calculations will still find occasion to refer patients. Indeed, the NCCN
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recommends that if a woman’s risk is calculated to be >20%, she should be referred to a genetics
specialist (National Comprehensive Care Network, 2015). Although using risk assessment
models can be time-intensive, billing codes can be used to cover associated costs (Himes, Root,
Gammon, Luthy, in review).
Regardless of the route PCPs take to refer women who may be at elevated risk to a
genetic specialist, an advantage to referring patients is that genetic specialists have been trained
to look for cancer syndromes beyond hereditary breast and ovarian cancer, caused by mutations
in BRCA1/2 genes. Genetic specialists may be more prepared to diagnose rare genetic disease
(Hampel, Bennett, Buchanan, Pearlman & Wiesner, 2015).
Last, USPSTF strongly recommends that when genetic testing is performed, that pre- and
post-test counseling with a genetics professional occur, as these professionals are most likely to
be able to counsel regarding the legal, personal, and potential financial costs of genetic testing, as
this is their area of expertise (Moyer, 2014). A similar caution comes from the American College
of Medical Genetics and Genomics Practice Guidelines, who write: “. . . genetic testing . . .
performed without such counseling by qualified clinicians has been associated with . . .
misinterpretation of genetic test results, inappropriate medical management, lack of informed
decision making, violation of established ethical standards, adverse psychosocial outcomes, and
costly, unnecessary genetic testing,” (Hampel, Bennett, Buchanan, Pearlman, & Wiesner, 2015,
p.71).
Conclusion
The purpose of this study was to assess the effectiveness of five tools recommended by
the USPSTF to identify women with concerning family histories of breast cancer who were
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appropriate for referral to genetics professionals for in-depth risk analysis. Although two models
identified the 14 participants at elevated risk (i.e., identified by the Claus model as having a
>15% lifetime breast cancer risk), only the Ontario-FHAT had a combination of sensitivity of
100% and a negative predictive value of 100%. Although the Ontario-FHAT had a lower
specificity and PPV, these results are not unexpected in a screening tool where the goal is to
identify all participants who are at elevated risk (high sensitivity), although necessarily some
who are not at risk will also be referred (lower specificity). The AUC findings were compared
and the five tools did not vary significantly from each other. Therefore, of the tools examined,
and particularly for clinicians who lack the time or skill to utilize risk assessment models to
calculate lifetime risk of breast cancer, this study suggests the Ontario-FHAT as the best among
the tools examined for determining which patients should be referred to genetic specialists.
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Table 1
Description and Examples Risk Models vs. Screening Tools

Description

Examples

Risk Assessment Models**:

BRCAPRO1
Claus2
Tyrer-Cuzick3
BOADICEA4

Screening Tools to Guide Referral:

Ontario-FHAT5
Manchester6
RST7
FHS-78
PAT9

Used as part of an in-depth risk assessment for hereditary
cancer syndromes and/or likelihood of carrying BRCA1/2
mutations. Requires specialized computer software.
Models take extensive family history into account. Used to
calculate risk for breast cancer (as % in number of years or
lifetime). Appropriate to use for purpose of determining
who to offer breast MRI as part of annual screening.

Designed to assist primary care providers identify women
who would benefit from referral to genetics specialists for
in-depth risk assessment. Paper/ pencil instruments that
require just a few minutes of time. These tools provide a
general assessment of breast cancer risk and/or likelihood
of carrying BRCA1/2 mutation. These are NOT to be used
for the purpose of determining who to offer breast MRI as
part of annual screening.

**Note, although the Gail model (Breast Cancer Risk Assessment Tool – BCRAT) will also calculate lifetime and
5-year risk, it is not recommended for use in determining who should be offered screening breast MRI because it
does not take extensive family history into account.
1

(Berry et al., 2002); 2 (Claus, Risch & Thompson, 1994); 3 (Tyrer, Duffy & Cuzick, 2004); 4 (Antoniou et al.,
2008); 5 Family History Assessment Tool (FHAT), also called Ontario-Family History Assessment Tool (OntarioFHAT), (Gilpin, Carson & Hunter, 2000); 6 Manchester Scoring System (Evans et al, 2004);
7
Referral Screening Tool (Bellcross, Lemke, Pape, Tess & Meisner, 2009); 8 Family History Screen-7 (AshtonProlla et al., 2009); 9 Pedigree Assessment Tool (Hoskins, Zwaagstra & Ranz, 2006).
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Table 2
Description and Original Validation of Five Screening Tools
Tool Name & Description
FHAT-Ontarioa
• No. of questions: 17
• Referral cut point: >10
• May use in Ashkenazi Jewish population? Yes
• Weighted questions? No
Note: maternal and paternal lines scored separately,
highest number used to estimate risk

Manchesterb
• No. of questions: 12
• Referral cut point (2 ways to score): >10 or 15
• May use in Ashkenazi Jewish population? No
• Weighted questions? Yes
Note: Screens for both BRCA1 and BRCA2
mutations individually and together

Original Validation Studies
Sample:
• Purposive sample, 184 participants (all with
approximately doubled lifetime risk due to family
history) recruited through Ontario cancer registry,
physician referrals, and a NIH local research study.
Evaluated:
• Tool’s ability to identify women who had a 22%
lifetime risk for breast cancer in either the Claus model
or BRCAPRO.

Results: Compared to Claus model
Sensitivity: 0.74
Specificity: 0.54
PPV1: 0.28
NPV2 0.90
AUC3: Not done.

•
•
•
•
•

(See author’s original work for other
comparisons)

Results: Compared to BRCAPRO
Sample:
● Convenience sample of 422 patients with a personal or • Sensitivity: 61%
family history of breast or ovarian cancer who presented
• Specificity: 44%
to cancer genetics clinicsb
• AUC 3 0.60
● Those of Ashkenazi heritage excluded from sample as
high risk
(See author’s original work for other
comparisons)
Evaluated:
● Tool’s ability to identify women who had a >10%
likelihood of carrying a BRCA1/2 gene mutation as
defined by several models/tools (BRCAPRO, Couch,
Frank1, Frank 2)
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Tool Name & Description
RSTc
• No. of questions: 18
• Referral cut point: >2
• May use in Ashkenazi Jewish population? Yes
• Weighted questions? Yes

Original Validation Studies
•

Sample:
Convenience sample of 2464 women undergoing
screening mammography.

Results: Compared to BOADICEA
• Sensitivity: 0.91
• Specificity: 0.76
• AUC3 0.84

Evaluated:
● Tool’s ability to identify women with a >10%
(See author’s original work for other
likelihood of carrying BRCA1/2 mutation as defined by
comparisons)
several models/tools (BOADICEA, BRCAPRO, Myriad
II) or an Ontario-FHAT score > 10

FHS-7d
• No. of questions: 7
• Referral cut point: >1
• May use in Ashkenazi Jewish population? Yes
• Weighted questions? No

Results: Compared to women who
Sample:
• Convenience sample of 1795 women to whom FHS-7 meet clinical criteria for hereditary
breast cancer syndromes (overall).
was applied during routine visits to primary care in
• Sensitivity: 0.88
southern Brazil.
• Specificity: 0.56
Evaluated:
• AUC3 0.83
● Tool’s ability to identify women with family history
(See author’s original work for other
consistent with high-risk hereditary breast cancer
comparisons)
syndromes. This included several hereditary breast
cancer syndromes.

PATe
• No. of questions: 5
• Referral cut point: >8
• May use in Ashkenazi Jewish population? Yes
• Weighted questions? Yes

Sample:
• Convenience sample of 3906 women presenting at
community hospital for screening mammography.

Evaluated:
● Tool’s ability to categorize women as “high BRCA
probability” vs. “low BRCA probability” as defined by
Note: maternal and paternal lines scored separately,
criteria developed by authors.
highest number used to estimate risk
● AUC3 for tool’s ability to identify women with > 10%
risk of carrying BRCA1/2 mutations as defined by the
Frank model.

Results: Compared to criteria
developed by authors
• Sensitivity: 100%
• Specificity: 93%
• Compared to Frank model
• AUC3 0.96
(See author’s original work for other
comparisons)
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Tool Name & Description
a

Original Validation Studies

Family History Assessment Tool, also called Ontario Family History Assessment Tool (Gilpin, Carson & Hunter, 2000).
Manchester Scoring System (Evans et al, 2004).
c
Referral Screening Tool (Bellcross, Lemke, Pape, Tess & Meisner, 2009).
d
Family History Screen-7 (Ashton-Prolla et al., 2009).
e
Pedigree Assessment Tool (Hoskins, Zwaagstra & Ranz, 2006).
1
PPV = Positive predictive value; 2NPV = negative predictive value; 3AUC = Area under curve.
b
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Table 3
Demographics
Category
Age

Race/
ethnicity
Education

Marital status

Total

Participants
n
(%)
40-49
50-59
60-69
70-74

37
28
14
5

Non-Hispanic White
Asian

83
1

(98.8)
(1.2)

High school/ GED
Some college
Vocational
2 year college
4 year college
Master's degree

13
15
8
9
28
11

(15.5)
(17.9)
(9.5)
(10.7)
(33.3)
(13.1)

Married
Member unmarried
couple
Separated
Divorced
Widowed
Never married

67

(79.8)

1
3
9
2
2

(1.2)
(3.6)
(10.7)
(2.4)
(2.4)

84

(44.0)
(33.3)
(16.7)
(6.0)

(100.0)
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Table 4
Performance Indicators of Five Screening Tools as Compared to Claus Model

Tool
FHAT-Ontarioa

Sensitivity Specificity
(%)
(%)

PPV

1

NPV

2

Number of Number of
elevated risk non-elevated
women
risk women
[95% CI]
referred
referred
0.72
14/14
45/71
[0.61-0.82]
AUC3

100

36.62

23.73

100

Manchesterb

57.14

64.79

24.24

88.46

0.65
[0.53-0.78]

8/14

25/71

RSTc

78.57

46.48

22.45

91.67

0.69
[0.55-0.82]

11/14

38/71

PATd

78.57

67.75

26.83

93.18

0.63
[0.50-0.75]

11/14

30/71

100

0

16.47

0

0.67
[0.57-0.77]

14/14

71/71

FHS-7e
a

Family History Assessment Tool, also called Ontario Family History Assessment Tool (Gilpin,
Carson & Hunter, 2000). bManchester Scoring System (Evans et al, 2004). cReferral Screening
Tool (Bellcross, Lemke, Pape, Tess & Meisner, 2009). dFamily History Screen-7 (Ashton-Prolla
et al., 2009). ePedigree Assessment Tool (Hoskins, Zwaagstra & Ranz, 2006). 1PPV = Positive
predictive value; 2NPV = negative predictive value; 3AUC = Area under curve
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Figure 1
ROC Curves for Five Screening Tools to Guide Referral

